Shuimu Biosciences

Shuimu Biosciences Ltd., a structure- and computation-driven innovative drug discovery company, owns the first commercial cryo-electron microscopy (cryo-EM) service platform in the Asia-Pacific region. Leveraging core technologies such as cryo-EM, computational chemistry, machine learning, and high-performance computing, Shuimu Biosciences is advancing digital innovation in small molecules, antibody drugs, protein degradation, gene therapy, and other fields, significantly enhancing the efficiency and success rate of drug discovery for global pharmaceutical companies.Founded at Tsinghua University in 2017, Shuimu Biosciences' core team comprises outstanding life and computational scientists, IT/internet experts, and pharmaceutical industry professionals. Since its inception, the company has successfully provided structural biology and drug discovery services to over 30 innovative pharmaceutical companies and top research institutions from China, the United States, and Europe.Shuimu Biosciences' new drug discovery technology effectively addresses the shortcomings of traditional drug development methods, such as unknown target structures, high randomness, long R&D cycles, and high costs, elevating structure-based drug discovery (SBDD) to a new level.